*As per the Insurance Regulatory and Development Authority of India (IRDAI), India will be the sixth-largest insurance market within a decade, leapfrogging Germany, Canada, Italy and South Korea.

* The number of MSMEs in the country is expected to grow from 6.38 crore, of which only 2.5 crore have ever availed credit from formal sources to approximately 7.5 crore in the coming times, growing ...

Ibrance is under clinical development by Pfizer and currently in Phase II for Chordoma. According to GlobalData, Phase II drugs for Chordoma does not have sufficient historical data to build an ...

Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled ...

The FDA has expanded the use of Pfizer’s Ibrance to include use in breast cancer in men based on a filing that drew heavily on post-marketing and real-world data.

Ibrance is not yet approved in Europe, but Pfizer says it will file the drug for use in its first-line indication with the European Medicines Agency in the second half of 2015. Related articles 10 ...